Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SN2001

Phase 1Biologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis B InfectionActive, not recruiting

Chronic Hepatitis B InfectionPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Chronic Hepatitis B Infection

NCT07059403

Clinical

Trials by Indication[1]

Chronic Hepatitis B Infection1 trial

A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of SN2001 in Healthy Adult Subjects

Active, not recruiting·CChimivac INC·Phase 1·NCT07059403·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SN2001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SN2001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SN2001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chimivac INC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CChimivac INC

Related News